Yeah, such big news AMRN didn't even bother to issue a PR about it - that's either IR falling flat on their face, or AMRN knows this has no real value - if they have no intention of testing it, which is almost certainly the case, then it means nothing except blocking some other company from combining GV with a PPAR to create a new drug. But adding a fibrate type drug comes with the exact same problem that a V+statin drug poses - too many different drugs to choose from and too many doses with each drug - there is no "one size fits all" combo drug regardless of what you choose to be the add-on drug.
Heck, even V is a compromise at 4 g/day - a 110 lb woman will have a much larger amount of serum EPA than a 280 lb man - if excess EPA is just excreted, no problem for the woman except wasted money, but that man is likely not getting the full benefit of V since he has a much lower concentration of EPA in his blood - about half as much as the woman. From https://www.omnicalculator.com/health/blood-volume , a 5'2" 110 woman has 3225 ml of blood, while a 6'0" 280 lb man has more than double the amount of blood, 6937 ml - they will clearly have a ~50% difference in EPA concentration in their blood before it's absorbed by cells. But it would have been too expensive to add a 6 g/day arm to R-IT, costs would have gone up significantly (> $100M), assuming they added patients to get good p values instead of splitting the 8000 patients into 3 smaller groups.
News 
Market Data 
Discover 
